Quest Diagnostics
676 hedge funds and large institutions have $12.8B invested in Quest Diagnostics in 2019 Q3 according to their latest regulatory filings, with 64 funds opening new positions, 254 increasing their positions, 208 reducing their positions, and 42 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
57% more call options, than puts
Call options by funds: $53.1M | Put options by funds: $33.9M
52% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 42
22% more repeat investments, than reductions
Existing positions increased: 254 | Existing positions reduced: 208
3% more funds holding
Funds holding: 654 → 676 (+22)
3% less capital invested
Capital invested by funds: $13.2B → $12.8B (-$411M)
1.88% less ownership
Funds ownership: 91.1% → 89.22% (-1.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$176M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$64.5M |
| 3 |
BlackRock
New York
|
+$61.5M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$51.5M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$50.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$802M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$120M |
| 3 |
Allianz Asset Management
Munich,
Germany
|
-$60.6M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$41.3M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$30.9M |
DGX Hedge Fund Activity: Q3 2019 in Review
676 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Quest Diagnostics (DGX) for Q3 2019, worth a combined $12.8B — down 3.1% from $13.2B a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new DGX positions and 42 closed out — a net gain of 22 holders — while 254 added to existing stakes and 208 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $176M. The largest seller was Macquarie Group, cutting an estimated $802M.
- 676 institutional investors held Quest Diagnostics (DGX) as of Q3 2019, up from 654 in Q2 2019.
- Funds reported $12.8B of Quest Diagnostics stock for Q3 2019, down 3.1% quarter-over-quarter.
- 64 funds opened new Quest Diagnostics positions in Q3 2019 and 42 closed out, a net change of +22 holders.
- The largest Quest Diagnostics buyer in Q3 2019 was JP Morgan Chase, an estimated $176M added.
- The largest Quest Diagnostics seller in Q3 2019 was Macquarie Group, an estimated $802M sold.
Based on aggregated 13F filings for Q3 2019.